CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia

PURPOSE: CPX-351 is a dual-drug liposomal encapsulation of cytarabine and daunorubicin that delivers a synergistic 5:1 drug ratio into leukemia cells to a greater extent than normal bone marrow cells. Prior clinical studies demonstrated a sustained drug ratio and exposure in vivo and prolonged survi...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Clin Oncol
Prif Awduron: Lancet, Jeffrey E., Uy, Geoffrey L., Cortes, Jorge E., Newell, Laura F., Lin, Tara L., Ritchie, Ellen K., Stuart, Robert K., Strickland, Stephen A., Hogge, Donna, Solomon, Scott R., Stone, Richard M., Bixby, Dale L., Kolitz, Jonathan E., Schiller, Gary J., Wieduwilt, Matthew J., Ryan, Daniel H., Hoering, Antje, Banerjee, Kamalika, Chiarella, Michael, Louie, Arthur C., Medeiros, Bruno C.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Clinical Oncology 2018
Pynciau:
RAPID COMMUNICATION
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6127025/
https://ncbi.nlm.nih.gov/pubmed/30024784
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.77.6112
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg